Current Open RFP
Product Development Platform 2022-002
The GHIT Fund announces an investment opportunity for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on a broad array of R&D activities, including:
- Lead optimization
- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)
- Clinical Development (Phase 1, 2, or 3 studies, manufacturing scale-up)
- Activities to support licensure and WHO prequalification
The investment scope for the RFP-PD-2022-002 is primarily focused on continuation projects, diagnostics projects, and projects beyond lead optimization (e.g. FIH and POC).
Interested applicants can find detailed information on the RFP and the Intent to Apply form below.
(The schedule is subject to change due to unforeseen circumstances.)
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release June 6, 2022
Intent to Apply No later than 10:00 am Tokyo time on July 4, 2022
*Applicants are encouraged to submit the ITA well in advance of the Full Proposal submission deadline shown below to secure sufficient time to prepare full proposal.
Submit via Editorial Manager® for Product Development
Platform (http://www.editorialmanager.com/ghitfund/)
Q&A
(RFP related questions)No later than 10:00 am Tokyo time on July 26, 2022
Submit questions to RFPResponse@ghitfund.org
Email Subject Line: GHIT-RFP-PD-2022-002_Questions
Full Proposal Due No later than 10:00 am Tokyo time on August 2, 2022
Submit via Editorial Manager® for Product Development
Platform (http://www.editorialmanager.com/ghitfund/)
Full Proposal templates
*Only eligible applicants will be invited to submit the full proposal and will receive an instruction to access the proposal templates below.
[Drug] [Vaccine] [Diagnostics]
Proposals Evaluation and Interview Processes August 2022 – February 2023
Notification of Results February 2023
Investment Agreement Fully Executed (Awarded Proposals) March 2023